Bolt Biotherapeutics

Bolt Biotherapeutics is a privately held biotechnology company based in San Francisco that is developing Boltbody™, a novel cancer treatment technology. The company is currently led by a team with extensive experience in oncology drug discovery and development. Additionally, Bolt Biotherapeutics was founded by Dr. Ed Engleman, a professor of pathology and medicine at Stanford University School of Medicine, and its platform is based on technology exclusively licensed from Stanford University.